neuromuscular blocking agents

Also found in: Dictionary, Encyclopedia.

neu·ro·mus·cu·lar block·ing a·gents

a group of drugs that prevents motor nerve endings from exciting skeletal muscle. They act either by competing for the neurotransmitter, acetylcholine (for example, D-tubocurarine, mivacurium, and pancuronium), or by first stimulating the postjunctional muscle membrane and subsequently desensitizing the muscle endplates to acetylcholine (for example, succinylcholine or decamethonium); used in surgery to produce paralysis and facilitate manipulation of muscles.

neu·ro·mus·cu·lar block·ing a·gents

(nūrō-mŭskyū-lăr bloking ājĕnts)
Drugs that prevent motor nerve endings from exciting skeletal muscle.


pertaining to nerve terminations in muscles.

neuromuscular blockade
deliberate paralysis of the motor end-plates; important in veterinary surgery for immobilization. It is effected by the use of competitive (non-depolarizing) agents such as d-tubocurarine, and depolarizing agents such as succinylcholine.
neuromuscular blocking agents
drugs capable of producing neuromuscular blockade (above).
neuromuscular junction
the point of junction of a nerve fiber with the muscle that it innervates. It includes an area of folded sarcolemma of the muscle fiber, and an axon terminal located in the folds and containing vesicles of the neurotransmitter acetylcholine. Called also myoneural junction.
neuromuscular junction disease
examples are tick paralysis, botulism, myasthenia gravis.
neuromuscular paralysis
paralysis caused by malfunction at the neuromuscular junction, e.g. after administration of a neuromuscular blocking agent. The paralysis may be flaccid or spastic.
phase-II neuromuscular block
alteration of the end-plate threshold to depolarization by acetylcholine following prolonged use of a depolarization agent such as succinylcholine.
neuromuscular spindle
consists of muscle fiber, afferent and efferent nerve endings and connective tissue; maintains muscle tone via stretch reflex mediated through two neurons at spinal cord level.
neuromuscular transmission
release of acetylcholine from the nerve ending and activation of the receptors in the muscle end-plate.
References in periodicals archive ?
In a previous study, 3 different neuromuscular blocking agents were applied locally to induce mydriasis in kestrels.
The testimony of veterinarians shows that the actual day-to-day euthanasia practices conform to the guidelines established by the Humane Society and the AVMA, and that neuromuscular blocking agents have no place in animal euthanasia.
an order to 'continue same meds' upon transfer from a critical care unit has led to continued use (sometimes fatal) of neuromuscular blocking agents for restless, but extubated patients.
This analysis may provide further insight into the future selection of rapidly metabolized neuromuscular blocking agents being considered for use as pharmacodynamic probes.
ICU patients receiving neuromuscular blocking agents should be observed clinically and blockade should be titrated to yield muscular twitch "train of four" testing at the level of one or two twitches.
Quantification of the neuromuscular blocking agent rocuronium and its putative metabolite 17-desacetylrocuronium in heparinized plasma by capillary gas chromatography using a nitrogen sensitive detector.
It is recommended that clinicians administering neuromuscular blocking agents, such as ZEMURON, employ a peripheral nerve stimulator to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered.
The introduction of the intermediate acting neuromuscular blocking agents vecuronium, cisatracurium and rocuronium may have led to complacency with respondents believing residual blockade is no longer a problem.
Neuromuscular blocking agents (NMBA) are drugs that cause skeletal muscle weakness or paralysis and therefore prevent movement.
Transdermal anticholinergenics, selective oral anticholinergenics, beta3-adrenergic receptor agonists and neuromuscular blocking agents are all being used to improve the patient experience of OAB therapeutics, as is onabotulinumtoxinA - Botox - which is being used off-label.
Cholinesterase inhibitors, such as galantamine HBr, are likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia.

Full browser ?